The Latest Breaking News from Abbott

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

There's a missing link between college and career.

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.

The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths

About three million devices are affected, though many may be expired or already used

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

For the previous edition of Deal Dispatch, click here.